Expect a sharp sell-off on the Phase 3 miss as the market reprices the stock without apazunersen upside. Monitor the expense reduction plan details and any potential pipeline salvage moves; the commercial business support language suggests management is pivoting to existing revenue streams.
RARE drugs
RARE drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 3 $14.85entry
- T+1 · 2mo ago +3.03%α +3.42% · $15.30
- T+5 · 2mo ago −3.70%α −2.56% · $14.30
- T+20 · 7w ago +2.49%α +3.68% · $15.22
- T+51 · todayOpen
- T+60 · in 13d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ultragenyx announced that its Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome failed to meet the primary endpoint (Bayley-4 cognitive raw score) and the key secondary endpoint (MDRI). The company will evaluate the program's disposition and implement significant expense reductions while supporting its commercial business. This is a major pipeline setback for a company with a $2.5B market cap that was likely pricing in some probability of success for this high-profile asset.
Key Facts
- Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score.
- The study also failed the key secondary endpoint of net response in Multidomain Responder Index (MDRI).
- No differences were observed between treated and control groups supporting efficacy in Bayley Cognition raw scores or MDRI.
- Safety profile was consistent with Phase 1/2.
- Company will evaluate the apazunersen program for disposition and implement significant expense reductions while supporting its growing commercial business.
Financial Impact
Phase 3 failure likely eliminates a major pipeline value driver; company will take significant expense reductions but no specific dollar amounts provided.
Risk Factors
- Complete write-off of apazunersen program value
- Potential for further pipeline setbacks if expense reductions impact other programs
- Uncertainty around magnitude and timing of expense reductions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-380165 |
| Document: 0001193125-26-380165-index.html | 0001193125-26-380165 |
| Document: 0001193125-26-380165.txt | 0001193125-26-380165 |
Track record
22 reports on RARE
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
- Nov 3, 202613d ago 8-K Mixed 6/10 No price data
- Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
- Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
- Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
- Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers